Comparative Pharmacology
Head-to-head clinical analysis: GENTAK versus STREPTOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAK versus STREPTOMYCIN SULFATE.
GENTAK vs STREPTOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis by causing misreading of mRNA and preventing initiation complex formation.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
Intramuscular: 15 mg/kg/day (max 1 g/day) divided every 12 hours; intraperitoneal: 1 g/dialysis cycle; intrathecal: 1 mg/kg/day.
None Documented
None Documented
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is 2-3 hours in patients with normal renal function. In anuria or severe renal impairment, half-life may extend to 50-100 hours. Neonates have a prolonged half-life of 5-10 hours due to immature renal function.
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Primarily renal excretion via glomerular filtration; 80-98% of the dose is excreted unchanged in urine within 24 hours. Minor biliary excretion (less than 1%). Fecal excretion is negligible.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic